Felbamate

Research use only, not for human use.

Felbamate (FBM) is a potent nonsedative anticonvulsant whose clinical effect may be related to the inhibition of N-methyl-D-aspartate (NMDA).

Felbamate (FBM) is a potent nonsedative anticonvulsant whose clinical effect may be related to the inhibition of N-methyl-D-aspartate (NMDA) . Felbamate (Felbatol) is an anticonvulsant drug used in the treatment of epilepsy. Felbamate is used to control some types of seizures in the treatment of epilepsy. Felbamate acts on the central nervous system (CNS) to make it more difficult for seizures to start or to continue. This medicine cannot cure epilepsy and will only work to control seizures for as long as you continue to use it. (In Vitro):Felbamate (W-554) is an anti-epileptic drug used in the treatment of epilepsy. It is used to treat partial seizures (with and without generalization) in adults and partial and generalized seizures associated with Lennox-Gastaut syndrome in children. However, an increased risk of potentially fatal aplastic anemia and/or liver failure limit the drugs usage to severe refractory epilepsy. Felbamate (W-554) has been proposed to a unique dual mechanism of action as a positive modulator of GABAA receptors and as a blocker of NMDA receptors, particularly isoforms containing the NR2B subunit. Although it is clear that felbamate does cause pharmacological inhibition of NMDA receptor of relevance of NMDA receptor blockade as a strategy for the treatment of human epilepsy has been questioned. Therefore, the importance of the effects of felbamate on NMDA receptors to its therapeutic action in epilepsy is uncertain.

Felbamate (W-554) is an anti-epileptic drug used in the treatment of epilepsy. It is used to treat partial seizures (with and without generalization) in adults and partial and generalized seizures associated with Lennox-Gastaut syndrome in children. However, an increased risk of potentially fatal aplastic anemia and/or liver failure limit the drugs usage to severe refractory epilepsy. Felbamate (W-554) has been proposed to a unique dual mechanism of action as a positive modulator of GABAA receptors and as a blocker of NMDA receptors, particularly isoforms containing the NR2B subunit. Although it is clear that felbamate does cause pharmacological inhibition of NMDA receptor of relevance of NMDA receptor blockade as a strategy for the treatment of human epilepsy has been questioned. Therefore, the importance of the effects of felbamate on NMDA receptors to its therapeutic action in epilepsy is uncertain.

——

ADD 03055

Membrane Transporter/Ion Channel

NMDAR

NMDA receptor

Neurological Disease

——

25451-15-4

238.24

C11H14N2O4

>98% (HPLC)

Ethanol: 3 mg/mL (12.59 mM); DMSO: 48 mg/mL (201.47 mM)

NC(OCC(C1=CC=CC=C1)COC(N)=O)=O

2-phenylpropane-1,3-diyl dicarbamate

(-20℃)

With Ice Pack

≥ 2 years